SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 63.99+4.7%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: A.J. Mullen3/21/2025 4:11:22 PM
2 Recommendations

Recommended By
DewDiligence_on_SI
OldAIMGuy

  Read Replies (1) of 52153
 
Message 35074195
The FDA is still working despite the firings. It approved an expansion of its approval for Amvuttra yesterday to include more patients with a genetic heart condition, ATTR. It’s marketed by Alnylam who have announced aggressive pricing. At twice the rate of existing competition. Amvuttra is injected quarterly, rather than orally daily. Alynlam claims greater compliance. It silences a gene, so it gets to the root of the cause, but the difference in effectiveness seem marginal. The big difference might lie in the payment procedure within Medicare – doctors will have an incentive to prescribe the injections. finance.yahoo.com. Alnylam is up 10%.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News